Skip to content
Fast Company Executive Board

The Fast Company Executive Board is a private, fee-based network of influential leaders, experts, executives, and entrepreneurs who share their insights with our audience.

Personalized medicine’s next frontier isn’t genetics

It’s sunlight—and here’s why.

[Photo: Getty Images]

Profile photo of Chris Brooks

Chief Strategy Officer · Solius Labs

Most of us log more hours outside during summer months than the rest of the year. Along with the longer days comes the annual wave of sunscreen chatter: which SPF to buy and warnings about ingredients. There’s also no shortage of dubious alternative recommendations online— from drinking watermelon juice to using “melatonin peptide” sprays.

Underneath the noise is a bigger shift. Medicine is moving away from one-size-fits-all advice, toward guidance built around an individual’s genetics and biomarkers. Sun exposure, one of the oldest inputs to human health, is only now starting to get the same treatment.

This year, there’s exciting regulatory news in this area. In June, the FDA cleared bemotrizinol, the first new active ingredient added to the U.S. sunscreen monograph since 1999. Bemotrizinol is broad-spectrum UVA/UVB light filter long available in Europe and Asia (and reason for sunscreen smuggling by Americans after European and Asian vacations). While the new ingredient is a small win, it’s also a reminder of how blunt our sunscreen tools still are: Even a better sunscreen is one formula, marketed the same way to everyone.

WHY WE NEED PRECISION SUNCARE

Not everyone is the same. We all have unique skin. In the United States, we mostly talk about skin tone using the Fitzpatrick scale, a 1-to-6 rating from very fair to deeply pigmented. It’s a useful shorthand, but plenty of people don’t fit neatly into one of six boxes. Dermatology’s evidence base, including sunscreen research and clinical imagery, has historically underrepresented darker skin. In fact, the international standard for SPF testing requires a skin-color range that excludes Fitzpatrick types 4, 5, and 6 from the test panel. That testing gap is a small example of a bigger pattern: sun advice built for an average person, when no one’s skin is average.

The case for personalizing sun exposure gets stronger once you separate ultraviolet A from ultraviolet B radiation. Richard Weller, a dermatologist whose lab first identified that human skin stores nitric oxide that UV light releases into the bloodstream, has spent two decades linking UVB exposure to measurable drops in blood pressure, with cardiovascular benefits no oral supplement can replicate. Other research ties UVB to immune regulation independent of vitamin D, including a rise in regulatory T-cells that calm autoimmune activity. It’s one reason why dermatologists prescribe narrowband UVB phototherapy for psoriasis, eczema, and vitiligo.

UVA AND UVB KEY DIFFERENCES

Journalist Rowan Jacobsen surveys this territory in In Defense of Sunlight. He argues that “just avoid the sun” messaging conflated UVA rays, which cause the most harm, with UVB rays, which carry real benefits, leading people to block the risk along with the benefits.

Jacobsen’s distinction cuts both ways, because UVB is also the scarce half of the equation. UVA passes through clouds and glass largely unblocked, which is why cloudy-day and through-the-window sunburns happen. UVB, the shorter wavelength behind those benefits, is blocked by clouds and glass and highly sensitive to the sun’s angle. It’s confined to a narrow time period— roughly two to three hours near solar noon—and only certain months of the year.

Where I live in Seattle, beneficial UVB disappears for four months a year. Even in Dallas, one of the sunniest big cities in the country, EPA data shows readings drop for a couple of months each winter to the low end of the moderate range, the point where meaningful UVB benefit starts. Add elevation, latitude, skin type, genetics, time of day, and season, and dosing the sun becomes nearly impossible: Most attempts to “get enough” naturally end in a mild to severe sunburn instead, which is exactly why sunscreen and shade remain the reliable default.

THE MEDICAL HORIZON

Two responses to the sun exposure issue are already taking shape. At the individual level, a handful of companies are building wearable devices and apps that help people track sunlight and time their exposure, a real challenge given how much of the year lacks usable UVB.

A different approach sidesteps natural light’s constraints: measuring a person’s skin tone and delivering a personalized UVB dose in a controlled setting instead of waiting on the sun’s schedule. This year, the FDA cleared the first over-the-counter device of this kind. It’s signal that this approach is moving from lab research toward something people can access in their daily lives. The goal of the device—created by Solius Labs where I serve as chief strategy officer—is to get enough UVB to stimulate a real benefit without unnecessary risk.

At the population level, the one-size-fits-all sun advice is also changing. For example, Cancer Council Australia released a revised position statement in 2024 grouping people into three tiers by skin type instead of one rule for everyone: full-time protection for very high skin cancer risk, protection once the UV index hits 3 for intermediate risk, and no routine protection for deeply pigmented skin, where vitamin D deficiency is the bigger risk. It’s built on the same premise driving personalized medicine elsewhere. Risk and benefit vary enough by individual that one blanket rule leaves people over- or underserved.

None of this undercuts dermatologists’ core message. Avoiding sunburn and overexposure is still sound advice and always will be. What personalization adds is a set of tools beyond that single blanket rule: informed choices about timing and protection based on who you actually are. Dermatological and public health guidance defaults to one rule for everyone because getting all these variables right on your own is hard, and getting it wrong carries real risk.

The takeaway isn’t that you should throw out your sunscreen this summer. It’s that sun exposure is likely the next place personalized medicine shows up in ordinary life, alongside genetic testing and personalized health metrics. Harnessing the health benefits of UVB light, rather than avoiding the sun altogether, requires a delicate balance to get a meaningful dose without courting unnecessary risk. As the research and technology catch up, it’s worth asking whether the one-size-fits-all sun advice you grew up with is still built for you.

Chris Brooks is the chief strategy officer of Solius Labs.